nodes	percent_of_prediction	percent_of_DWPC	metapath
Ifosfamide—CYP2A6—Prednisolone—multiple sclerosis	0.0943	0.162	CbGbCtD
Ifosfamide—CYP2A6—Dexamethasone—multiple sclerosis	0.0556	0.0954	CbGbCtD
Ifosfamide—CYP3A4—Fingolimod—multiple sclerosis	0.0456	0.0783	CbGbCtD
Ifosfamide—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.038	0.0652	CbGbCtD
Ifosfamide—CYP3A7—Dexamethasone—multiple sclerosis	0.038	0.0652	CbGbCtD
Ifosfamide—CYP2C19—Prednisone—multiple sclerosis	0.0369	0.0632	CbGbCtD
Ifosfamide—CYP2B6—Dexamethasone—multiple sclerosis	0.0362	0.0621	CbGbCtD
Ifosfamide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0294	0.0505	CbGbCtD
Ifosfamide—CYP3A5—Dexamethasone—multiple sclerosis	0.0285	0.0489	CbGbCtD
Ifosfamide—CYP2C8—Dexamethasone—multiple sclerosis	0.0274	0.0471	CbGbCtD
Ifosfamide—CYP2C19—Dexamethasone—multiple sclerosis	0.023	0.0395	CbGbCtD
Ifosfamide—CYP3A4—Triamcinolone—multiple sclerosis	0.0223	0.0382	CbGbCtD
Ifosfamide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0215	0.0368	CbGbCtD
Ifosfamide—CYP2C9—Dexamethasone—multiple sclerosis	0.0191	0.0328	CbGbCtD
Ifosfamide—CYP3A4—Betamethasone—multiple sclerosis	0.0191	0.0328	CbGbCtD
Ifosfamide—CYP3A4—Prednisolone—multiple sclerosis	0.0189	0.0324	CbGbCtD
Ifosfamide—CYP3A4—Prednisone—multiple sclerosis	0.0178	0.0306	CbGbCtD
Ifosfamide—CYP3A4—Dexamethasone—multiple sclerosis	0.0111	0.0191	CbGbCtD
Ifosfamide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000674	0.0139	CbGpPWpGaD
Ifosfamide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000674	0.0139	CbGpPWpGaD
Ifosfamide—CYP3A7—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000665	0.0137	CbGpPWpGaD
Ifosfamide—CYP3A7—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000665	0.0137	CbGpPWpGaD
Ifosfamide—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000618	0.0127	CbGpPWpGaD
Ifosfamide—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000618	0.0127	CbGpPWpGaD
Ifosfamide—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000609	0.0125	CbGpPWpGaD
Ifosfamide—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000609	0.0125	CbGpPWpGaD
Ifosfamide—CYP3A7—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000546	0.0112	CbGpPWpGaD
Ifosfamide—CYP3A7—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000546	0.0112	CbGpPWpGaD
Ifosfamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000541	0.0111	CbGpPWpGaD
Ifosfamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000541	0.0111	CbGpPWpGaD
Ifosfamide—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.000541	0.0111	CbGpPWpGaD
Ifosfamide—PTGS1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000529	0.0109	CbGpPWpGaD
Ifosfamide—PTGS1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000529	0.0109	CbGpPWpGaD
Ifosfamide—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000501	0.0103	CbGpPWpGaD
Ifosfamide—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000501	0.0103	CbGpPWpGaD
Ifosfamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000498	0.0103	CbGpPWpGaD
Ifosfamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000498	0.0103	CbGpPWpGaD
Ifosfamide—CYP2B6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000492	0.0101	CbGpPWpGaD
Ifosfamide—CYP2B6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000492	0.0101	CbGpPWpGaD
Ifosfamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000487	0.01	CbGpPWpGaD
Ifosfamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000487	0.01	CbGpPWpGaD
Ifosfamide—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000481	0.00989	CbGpPWpGaD
Ifosfamide—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000481	0.00989	CbGpPWpGaD
Ifosfamide—CYP2C18—Biological oxidations—CYP27B1—multiple sclerosis	0.000436	0.00898	CbGpPWpGaD
Ifosfamide—CYP2C18—Biological oxidations—CYP24A1—multiple sclerosis	0.000436	0.00898	CbGpPWpGaD
Ifosfamide—CYP2C18—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00043	0.00886	CbGpPWpGaD
Ifosfamide—CYP2C18—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00043	0.00886	CbGpPWpGaD
Ifosfamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000422	0.00868	CbGpPWpGaD
Ifosfamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000422	0.00868	CbGpPWpGaD
Ifosfamide—CYP2C8—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000416	0.00857	CbGpPWpGaD
Ifosfamide—CYP2C8—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000416	0.00857	CbGpPWpGaD
Ifosfamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000404	0.00831	CbGpPWpGaD
Ifosfamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000404	0.00831	CbGpPWpGaD
Ifosfamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000395	0.00812	CbGpPWpGaD
Ifosfamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000395	0.00812	CbGpPWpGaD
Ifosfamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000377	0.00775	CbGpPWpGaD
Ifosfamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000377	0.00775	CbGpPWpGaD
Ifosfamide—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000372	0.00765	CbGpPWpGaD
Ifosfamide—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000372	0.00765	CbGpPWpGaD
Ifosfamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000357	0.00734	CbGpPWpGaD
Ifosfamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000357	0.00734	CbGpPWpGaD
Ifosfamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000343	0.00706	CbGpPWpGaD
Ifosfamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000343	0.00706	CbGpPWpGaD
Ifosfamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000342	0.00704	CbGpPWpGaD
Ifosfamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000342	0.00704	CbGpPWpGaD
Ifosfamide—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000339	0.00697	CbGpPWpGaD
Ifosfamide—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000339	0.00697	CbGpPWpGaD
Ifosfamide—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000316	0.0065	CbGpPWpGaD
Ifosfamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000305	0.00628	CbGpPWpGaD
Ifosfamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000305	0.00628	CbGpPWpGaD
Ifosfamide—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.00029	0.00597	CbGpPWpGaD
Ifosfamide—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.00029	0.00597	CbGpPWpGaD
Ifosfamide—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000286	0.00589	CbGpPWpGaD
Ifosfamide—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000286	0.00589	CbGpPWpGaD
Ifosfamide—PTGS1—Biological oxidations—CYP27B1—multiple sclerosis	0.000281	0.00579	CbGpPWpGaD
Ifosfamide—PTGS1—Biological oxidations—CYP24A1—multiple sclerosis	0.000281	0.00579	CbGpPWpGaD
Ifosfamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000278	0.00573	CbGpPWpGaD
Ifosfamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000278	0.00573	CbGpPWpGaD
Ifosfamide—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000266	0.00547	CbGpPWpGaD
Ifosfamide—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000266	0.00547	CbGpPWpGaD
Ifosfamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000257	0.00528	CbGpPWpGaD
Ifosfamide—CYP2C18—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000228	0.00469	CbGpPWpGaD
Ifosfamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000226	0.00466	CbGpPWpGaD
Ifosfamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000226	0.00466	CbGpPWpGaD
Ifosfamide—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000223	0.0046	CbGpPWpGaD
Ifosfamide—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000223	0.0046	CbGpPWpGaD
Ifosfamide—CYP2B6—Biological oxidations—CYP27B1—multiple sclerosis	0.000215	0.00442	CbGpPWpGaD
Ifosfamide—CYP2B6—Biological oxidations—CYP24A1—multiple sclerosis	0.000215	0.00442	CbGpPWpGaD
Ifosfamide—CYP2B6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000212	0.00435	CbGpPWpGaD
Ifosfamide—CYP2B6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000212	0.00435	CbGpPWpGaD
Ifosfamide—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.00021	0.00432	CbGpPWpGaD
Ifosfamide—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.00021	0.00432	CbGpPWpGaD
Ifosfamide—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000207	0.00426	CbGpPWpGaD
Ifosfamide—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000207	0.00426	CbGpPWpGaD
Ifosfamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000203	0.00418	CbGpPWpGaD
Ifosfamide—PTGS1—Overview of nanoparticle effects—TNF—multiple sclerosis	0.000198	0.00408	CbGpPWpGaD
Ifosfamide—CYP2C18—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000185	0.0038	CbGpPWpGaD
Ifosfamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000184	0.00378	CbGpPWpGaD
Ifosfamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000184	0.00378	CbGpPWpGaD
Ifosfamide—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000182	0.00374	CbGpPWpGaD
Ifosfamide—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000182	0.00374	CbGpPWpGaD
Ifosfamide—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000179	0.00369	CbGpPWpGaD
Ifosfamide—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000179	0.00369	CbGpPWpGaD
Ifosfamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000177	0.00364	CbGpPWpGaD
Ifosfamide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000176	0.00363	CbGpPWpGaD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000169	0.000459	CcSEcCtD
Ifosfamide—Dermatitis—Azathioprine—multiple sclerosis	0.000169	0.000459	CcSEcCtD
Ifosfamide—Flushing—Prednisone—multiple sclerosis	0.000169	0.000458	CcSEcCtD
Ifosfamide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000169	0.000458	CcSEcCtD
Ifosfamide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000169	0.000458	CcSEcCtD
Ifosfamide—Discomfort—Triamcinolone—multiple sclerosis	0.000169	0.000458	CcSEcCtD
Ifosfamide—Discomfort—Methylprednisolone—multiple sclerosis	0.000168	0.000457	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000168	0.000456	CcSEcCtD
Ifosfamide—Renal failure—Methotrexate—multiple sclerosis	0.000167	0.000452	CcSEcCtD
Ifosfamide—Angioedema—Betamethasone—multiple sclerosis	0.000166	0.000451	CcSEcCtD
Ifosfamide—Angioedema—Dexamethasone—multiple sclerosis	0.000166	0.000451	CcSEcCtD
Ifosfamide—Stomatitis—Methotrexate—multiple sclerosis	0.000165	0.000448	CcSEcCtD
Ifosfamide—Angiopathy—Prednisone—multiple sclerosis	0.000165	0.000448	CcSEcCtD
Ifosfamide—Conjunctivitis—Methotrexate—multiple sclerosis	0.000165	0.000447	CcSEcCtD
Ifosfamide—Confusional state—Methylprednisolone—multiple sclerosis	0.000165	0.000447	CcSEcCtD
Ifosfamide—Immune system disorder—Prednisone—multiple sclerosis	0.000164	0.000446	CcSEcCtD
Ifosfamide—Malaise—Betamethasone—multiple sclerosis	0.000164	0.000445	CcSEcCtD
Ifosfamide—Malaise—Dexamethasone—multiple sclerosis	0.000164	0.000445	CcSEcCtD
Ifosfamide—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000164	0.000444	CcSEcCtD
Ifosfamide—Oedema—Triamcinolone—multiple sclerosis	0.000164	0.000444	CcSEcCtD
Ifosfamide—Vertigo—Betamethasone—multiple sclerosis	0.000163	0.000444	CcSEcCtD
Ifosfamide—Vertigo—Dexamethasone—multiple sclerosis	0.000163	0.000444	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000163	0.000443	CcSEcCtD
Ifosfamide—Arrhythmia—Prednisone—multiple sclerosis	0.000163	0.000441	CcSEcCtD
Ifosfamide—Infection—Triamcinolone—multiple sclerosis	0.000163	0.000441	CcSEcCtD
Ifosfamide—Infection—Methylprednisolone—multiple sclerosis	0.000162	0.00044	CcSEcCtD
Ifosfamide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000162	0.00334	CbGpPWpGaD
Ifosfamide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000162	0.00334	CbGpPWpGaD
Ifosfamide—Haematuria—Methotrexate—multiple sclerosis	0.000162	0.000438	CcSEcCtD
Ifosfamide—Alopecia—Prednisone—multiple sclerosis	0.000161	0.000436	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00016	0.000435	CcSEcCtD
Ifosfamide—PTGS1—Overview of nanoparticle effects—IL6—multiple sclerosis	0.00016	0.0033	CbGpPWpGaD
Ifosfamide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00016	0.000434	CcSEcCtD
Ifosfamide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00016	0.00329	CbGpPWpGaD
Ifosfamide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00016	0.00329	CbGpPWpGaD
Ifosfamide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00016	0.000434	CcSEcCtD
Ifosfamide—Paraesthesia—Prednisolone—multiple sclerosis	0.00016	0.000434	CcSEcCtD
Ifosfamide—Mental disorder—Prednisone—multiple sclerosis	0.000159	0.000433	CcSEcCtD
Ifosfamide—Nausea—Azathioprine—multiple sclerosis	0.000159	0.000432	CcSEcCtD
Ifosfamide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000159	0.00043	CcSEcCtD
Ifosfamide—Erythema—Prednisone—multiple sclerosis	0.000158	0.00043	CcSEcCtD
Ifosfamide—Malnutrition—Prednisone—multiple sclerosis	0.000158	0.00043	CcSEcCtD
Ifosfamide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000158	0.000429	CcSEcCtD
Ifosfamide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000158	0.000429	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000158	0.000428	CcSEcCtD
Ifosfamide—Convulsion—Dexamethasone—multiple sclerosis	0.000158	0.000428	CcSEcCtD
Ifosfamide—Convulsion—Betamethasone—multiple sclerosis	0.000158	0.000428	CcSEcCtD
Ifosfamide—Hypertension—Dexamethasone—multiple sclerosis	0.000157	0.000426	CcSEcCtD
Ifosfamide—Hypertension—Betamethasone—multiple sclerosis	0.000157	0.000426	CcSEcCtD
Ifosfamide—Asthenia—Mitoxantrone—multiple sclerosis	0.000156	0.000422	CcSEcCtD
Ifosfamide—Myalgia—Dexamethasone—multiple sclerosis	0.000155	0.00042	CcSEcCtD
Ifosfamide—Myalgia—Betamethasone—multiple sclerosis	0.000155	0.00042	CcSEcCtD
Ifosfamide—Discomfort—Betamethasone—multiple sclerosis	0.000153	0.000415	CcSEcCtD
Ifosfamide—Discomfort—Dexamethasone—multiple sclerosis	0.000153	0.000415	CcSEcCtD
Ifosfamide—Haemoglobin—Methotrexate—multiple sclerosis	0.000153	0.000415	CcSEcCtD
Ifosfamide—Hypotension—Methylprednisolone—multiple sclerosis	0.000153	0.000414	CcSEcCtD
Ifosfamide—Pain—Prednisolone—multiple sclerosis	0.000152	0.000413	CcSEcCtD
Ifosfamide—Haemorrhage—Methotrexate—multiple sclerosis	0.000152	0.000413	CcSEcCtD
Ifosfamide—Hepatitis—Methotrexate—multiple sclerosis	0.000152	0.000413	CcSEcCtD
Ifosfamide—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000152	0.00312	CbGpPWpGaD
Ifosfamide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.00015	0.000408	CcSEcCtD
Ifosfamide—Vision blurred—Prednisone—multiple sclerosis	0.000149	0.000405	CcSEcCtD
Ifosfamide—Urethral disorder—Methotrexate—multiple sclerosis	0.000149	0.000405	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000149	0.000405	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000149	0.000404	CcSEcCtD
Ifosfamide—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000148	0.000403	CcSEcCtD
Ifosfamide—Oedema—Dexamethasone—multiple sclerosis	0.000148	0.000403	CcSEcCtD
Ifosfamide—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000148	0.000403	CcSEcCtD
Ifosfamide—Oedema—Betamethasone—multiple sclerosis	0.000148	0.000403	CcSEcCtD
Ifosfamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000148	0.000403	CcSEcCtD
Ifosfamide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000148	0.00304	CbGpPWpGaD
Ifosfamide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000148	0.00304	CbGpPWpGaD
Ifosfamide—Infection—Betamethasone—multiple sclerosis	0.000148	0.0004	CcSEcCtD
Ifosfamide—Infection—Dexamethasone—multiple sclerosis	0.000148	0.0004	CcSEcCtD
Ifosfamide—Ill-defined disorder—Prednisone—multiple sclerosis	0.000147	0.000399	CcSEcCtD
Ifosfamide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000147	0.000399	CcSEcCtD
Ifosfamide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000147	0.000398	CcSEcCtD
Ifosfamide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000147	0.000398	CcSEcCtD
Ifosfamide—Visual impairment—Methotrexate—multiple sclerosis	0.000147	0.000398	CcSEcCtD
Ifosfamide—Anaemia—Prednisone—multiple sclerosis	0.000146	0.000397	CcSEcCtD
Ifosfamide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000146	0.000396	CcSEcCtD
Ifosfamide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000146	0.003	CbGpPWpGaD
Ifosfamide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000146	0.003	CbGpPWpGaD
Ifosfamide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000146	0.000395	CcSEcCtD
Ifosfamide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000146	0.000395	CcSEcCtD
Ifosfamide—Agitation—Prednisone—multiple sclerosis	0.000146	0.000395	CcSEcCtD
Ifosfamide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000145	0.000394	CcSEcCtD
Ifosfamide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000145	0.000394	CcSEcCtD
Ifosfamide—Angioedema—Prednisone—multiple sclerosis	0.000145	0.000393	CcSEcCtD
Ifosfamide—Erythema multiforme—Methotrexate—multiple sclerosis	0.000144	0.00039	CcSEcCtD
Ifosfamide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000144	0.000389	CcSEcCtD
Ifosfamide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000144	0.000389	CcSEcCtD
Ifosfamide—Malaise—Prednisone—multiple sclerosis	0.000143	0.000388	CcSEcCtD
Ifosfamide—Vertigo—Prednisone—multiple sclerosis	0.000142	0.000386	CcSEcCtD
Ifosfamide—Eye disorder—Methotrexate—multiple sclerosis	0.000142	0.000386	CcSEcCtD
Ifosfamide—Tinnitus—Methotrexate—multiple sclerosis	0.000142	0.000385	CcSEcCtD
Ifosfamide—Anorexia—Dexamethasone—multiple sclerosis	0.000142	0.000384	CcSEcCtD
Ifosfamide—Anorexia—Betamethasone—multiple sclerosis	0.000142	0.000384	CcSEcCtD
Ifosfamide—Urticaria—Prednisolone—multiple sclerosis	0.000141	0.000384	CcSEcCtD
Ifosfamide—Cardiac disorder—Methotrexate—multiple sclerosis	0.000141	0.000383	CcSEcCtD
Ifosfamide—Fatigue—Triamcinolone—multiple sclerosis	0.000141	0.000383	CcSEcCtD
Ifosfamide—Fatigue—Methylprednisolone—multiple sclerosis	0.000141	0.000382	CcSEcCtD
Ifosfamide—Pain—Triamcinolone—multiple sclerosis	0.00014	0.00038	CcSEcCtD
Ifosfamide—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000139	0.00286	CbGpPWpGaD
Ifosfamide—Hypotension—Betamethasone—multiple sclerosis	0.000139	0.000376	CcSEcCtD
Ifosfamide—Hypotension—Dexamethasone—multiple sclerosis	0.000139	0.000376	CcSEcCtD
Ifosfamide—Angiopathy—Methotrexate—multiple sclerosis	0.000138	0.000374	CcSEcCtD
Ifosfamide—Vomiting—Mitoxantrone—multiple sclerosis	0.000138	0.000374	CcSEcCtD
Ifosfamide—Immune system disorder—Methotrexate—multiple sclerosis	0.000137	0.000373	CcSEcCtD
Ifosfamide—Convulsion—Prednisone—multiple sclerosis	0.000137	0.000372	CcSEcCtD
Ifosfamide—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000137	0.000372	CcSEcCtD
Ifosfamide—Hypertension—Prednisone—multiple sclerosis	0.000137	0.000371	CcSEcCtD
Ifosfamide—Rash—Mitoxantrone—multiple sclerosis	0.000137	0.000371	CcSEcCtD
Ifosfamide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000137	0.000371	CcSEcCtD
Ifosfamide—Chills—Methotrexate—multiple sclerosis	0.000136	0.00037	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000135	0.000367	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000135	0.000367	CcSEcCtD
Ifosfamide—Arthralgia—Prednisone—multiple sclerosis	0.000135	0.000366	CcSEcCtD
Ifosfamide—Myalgia—Prednisone—multiple sclerosis	0.000135	0.000366	CcSEcCtD
Ifosfamide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000135	0.000366	CcSEcCtD
Ifosfamide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000135	0.000365	CcSEcCtD
Ifosfamide—Alopecia—Methotrexate—multiple sclerosis	0.000134	0.000365	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000134	0.000363	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000134	0.000362	CcSEcCtD
Ifosfamide—Paraesthesia—Betamethasone—multiple sclerosis	0.000133	0.000362	CcSEcCtD
Ifosfamide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000133	0.000362	CcSEcCtD
Ifosfamide—Discomfort—Prednisone—multiple sclerosis	0.000133	0.000362	CcSEcCtD
Ifosfamide—Mental disorder—Methotrexate—multiple sclerosis	0.000133	0.000362	CcSEcCtD
Ifosfamide—Malnutrition—Methotrexate—multiple sclerosis	0.000132	0.000359	CcSEcCtD
Ifosfamide—Erythema—Methotrexate—multiple sclerosis	0.000132	0.000359	CcSEcCtD
Ifosfamide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000131	0.000356	CcSEcCtD
Ifosfamide—Urticaria—Triamcinolone—multiple sclerosis	0.00013	0.000353	CcSEcCtD
Ifosfamide—Urticaria—Methylprednisolone—multiple sclerosis	0.00013	0.000352	CcSEcCtD
Ifosfamide—Body temperature increased—Triamcinolone—multiple sclerosis	0.000129	0.000351	CcSEcCtD
Ifosfamide—Anaphylactic shock—Prednisone—multiple sclerosis	0.000129	0.000351	CcSEcCtD
Ifosfamide—Oedema—Prednisone—multiple sclerosis	0.000129	0.000351	CcSEcCtD
Ifosfamide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000129	0.00035	CcSEcCtD
Ifosfamide—Decreased appetite—Betamethasone—multiple sclerosis	0.000129	0.00035	CcSEcCtD
Ifosfamide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000129	0.00035	CcSEcCtD
Ifosfamide—Nausea—Mitoxantrone—multiple sclerosis	0.000129	0.00035	CcSEcCtD
Ifosfamide—Infection—Prednisone—multiple sclerosis	0.000128	0.000349	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000128	0.000348	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000128	0.000348	CcSEcCtD
Ifosfamide—Fatigue—Betamethasone—multiple sclerosis	0.000128	0.000347	CcSEcCtD
Ifosfamide—Fatigue—Dexamethasone—multiple sclerosis	0.000128	0.000347	CcSEcCtD
Ifosfamide—Pain—Dexamethasone—multiple sclerosis	0.000127	0.000345	CcSEcCtD
Ifosfamide—Pain—Betamethasone—multiple sclerosis	0.000127	0.000345	CcSEcCtD
Ifosfamide—Nervous system disorder—Prednisone—multiple sclerosis	0.000127	0.000344	CcSEcCtD
Ifosfamide—Skin disorder—Prednisone—multiple sclerosis	0.000126	0.000341	CcSEcCtD
Ifosfamide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000125	0.000339	CcSEcCtD
Ifosfamide—Vision blurred—Methotrexate—multiple sclerosis	0.000125	0.000339	CcSEcCtD
Ifosfamide—Anorexia—Prednisone—multiple sclerosis	0.000123	0.000334	CcSEcCtD
Ifosfamide—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000123	0.00253	CbGpPWpGaD
Ifosfamide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000123	0.000333	CcSEcCtD
Ifosfamide—Anaemia—Methotrexate—multiple sclerosis	0.000122	0.000332	CcSEcCtD
Ifosfamide—Feeling abnormal—Betamethasone—multiple sclerosis	0.000122	0.000332	CcSEcCtD
Ifosfamide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000122	0.000332	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000121	0.000329	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000121	0.000329	CcSEcCtD
Ifosfamide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000121	0.000327	CcSEcCtD
Ifosfamide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00012	0.000326	CcSEcCtD
Ifosfamide—Malaise—Methotrexate—multiple sclerosis	0.000119	0.000324	CcSEcCtD
Ifosfamide—PTGS1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000119	0.00245	CbGpPWpGaD
Ifosfamide—Vertigo—Methotrexate—multiple sclerosis	0.000119	0.000323	CcSEcCtD
Ifosfamide—Leukopenia—Methotrexate—multiple sclerosis	0.000119	0.000322	CcSEcCtD
Ifosfamide—PTGS1—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000118	0.00243	CbGpPWpGaD
Ifosfamide—Urticaria—Betamethasone—multiple sclerosis	0.000118	0.00032	CcSEcCtD
Ifosfamide—Urticaria—Dexamethasone—multiple sclerosis	0.000118	0.00032	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000118	0.00032	CcSEcCtD
Ifosfamide—Dizziness—Prednisolone—multiple sclerosis	0.000118	0.000319	CcSEcCtD
Ifosfamide—Asthenia—Triamcinolone—multiple sclerosis	0.000117	0.000319	CcSEcCtD
Ifosfamide—Body temperature increased—Dexamethasone—multiple sclerosis	0.000117	0.000318	CcSEcCtD
Ifosfamide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000117	0.000318	CcSEcCtD
Ifosfamide—Abdominal pain—Betamethasone—multiple sclerosis	0.000117	0.000318	CcSEcCtD
Ifosfamide—Body temperature increased—Betamethasone—multiple sclerosis	0.000117	0.000318	CcSEcCtD
Ifosfamide—Asthenia—Methylprednisolone—multiple sclerosis	0.000117	0.000318	CcSEcCtD
Ifosfamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000117	0.0024	CbGpPWpGaD
Ifosfamide—Paraesthesia—Prednisone—multiple sclerosis	0.000116	0.000315	CcSEcCtD
Ifosfamide—Pruritus—Triamcinolone—multiple sclerosis	0.000116	0.000314	CcSEcCtD
Ifosfamide—Cough—Methotrexate—multiple sclerosis	0.000116	0.000314	CcSEcCtD
Ifosfamide—Pruritus—Methylprednisolone—multiple sclerosis	0.000116	0.000313	CcSEcCtD
Ifosfamide—Convulsion—Methotrexate—multiple sclerosis	0.000115	0.000311	CcSEcCtD
Ifosfamide—Arthralgia—Methotrexate—multiple sclerosis	0.000113	0.000306	CcSEcCtD
Ifosfamide—Chest pain—Methotrexate—multiple sclerosis	0.000113	0.000306	CcSEcCtD
Ifosfamide—Myalgia—Methotrexate—multiple sclerosis	0.000113	0.000306	CcSEcCtD
Ifosfamide—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000113	0.00232	CbGpPWpGaD
Ifosfamide—Decreased appetite—Prednisone—multiple sclerosis	0.000112	0.000305	CcSEcCtD
Ifosfamide—Rash—Prednisolone—multiple sclerosis	0.000112	0.000304	CcSEcCtD
Ifosfamide—Dermatitis—Prednisolone—multiple sclerosis	0.000112	0.000304	CcSEcCtD
Ifosfamide—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000112	0.00231	CbGpPWpGaD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000112	0.000304	CcSEcCtD
Ifosfamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000112	0.000303	CcSEcCtD
Ifosfamide—Fatigue—Prednisone—multiple sclerosis	0.000111	0.000302	CcSEcCtD
Ifosfamide—Discomfort—Methotrexate—multiple sclerosis	0.000111	0.000302	CcSEcCtD
Ifosfamide—Constipation—Prednisone—multiple sclerosis	0.000111	0.0003	CcSEcCtD
Ifosfamide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.00011	0.00225	CbGpPWpGaD
Ifosfamide—Confusional state—Methotrexate—multiple sclerosis	0.000109	0.000296	CcSEcCtD
Ifosfamide—Dizziness—Triamcinolone—multiple sclerosis	0.000108	0.000294	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000108	0.000293	CcSEcCtD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000108	0.00222	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000108	0.00222	CbGpPWpGaD
Ifosfamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000108	0.000293	CcSEcCtD
Ifosfamide—Infection—Methotrexate—multiple sclerosis	0.000107	0.000291	CcSEcCtD
Ifosfamide—Feeling abnormal—Prednisone—multiple sclerosis	0.000107	0.000289	CcSEcCtD
Ifosfamide—Asthenia—Dexamethasone—multiple sclerosis	0.000107	0.000289	CcSEcCtD
Ifosfamide—Asthenia—Betamethasone—multiple sclerosis	0.000107	0.000289	CcSEcCtD
Ifosfamide—Nervous system disorder—Methotrexate—multiple sclerosis	0.000106	0.000288	CcSEcCtD
Ifosfamide—CYP2C18—Metabolism—SRM—multiple sclerosis	0.000106	0.00218	CbGpPWpGaD
Ifosfamide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000106	0.000287	CcSEcCtD
Ifosfamide—PTGS1—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000106	0.00218	CbGpPWpGaD
Ifosfamide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000106	0.000287	CcSEcCtD
Ifosfamide—Nausea—Prednisolone—multiple sclerosis	0.000106	0.000287	CcSEcCtD
Ifosfamide—Pruritus—Dexamethasone—multiple sclerosis	0.000105	0.000285	CcSEcCtD
Ifosfamide—Pruritus—Betamethasone—multiple sclerosis	0.000105	0.000285	CcSEcCtD
Ifosfamide—Skin disorder—Methotrexate—multiple sclerosis	0.000105	0.000285	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000104	0.000283	CcSEcCtD
Ifosfamide—Vomiting—Triamcinolone—multiple sclerosis	0.000104	0.000282	CcSEcCtD
Ifosfamide—Vomiting—Methylprednisolone—multiple sclerosis	0.000104	0.000282	CcSEcCtD
Ifosfamide—Rash—Triamcinolone—multiple sclerosis	0.000103	0.00028	CcSEcCtD
Ifosfamide—Dermatitis—Triamcinolone—multiple sclerosis	0.000103	0.00028	CcSEcCtD
Ifosfamide—Anorexia—Methotrexate—multiple sclerosis	0.000103	0.000279	CcSEcCtD
Ifosfamide—Rash—Methylprednisolone—multiple sclerosis	0.000103	0.000279	CcSEcCtD
Ifosfamide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000103	0.000279	CcSEcCtD
Ifosfamide—Urticaria—Prednisone—multiple sclerosis	0.000103	0.000279	CcSEcCtD
Ifosfamide—Abdominal pain—Prednisone—multiple sclerosis	0.000102	0.000277	CcSEcCtD
Ifosfamide—Body temperature increased—Prednisone—multiple sclerosis	0.000102	0.000277	CcSEcCtD
Ifosfamide—Diarrhoea—Betamethasone—multiple sclerosis	0.000102	0.000276	CcSEcCtD
Ifosfamide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000102	0.000276	CcSEcCtD
Ifosfamide—Hypotension—Methotrexate—multiple sclerosis	0.000101	0.000274	CcSEcCtD
Ifosfamide—PTGS1—Selenium Micronutrient Network—ALB—multiple sclerosis	9.86e-05	0.00203	CbGpPWpGaD
Ifosfamide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	9.85e-05	0.000267	CcSEcCtD
Ifosfamide—Dizziness—Dexamethasone—multiple sclerosis	9.82e-05	0.000266	CcSEcCtD
Ifosfamide—Dizziness—Betamethasone—multiple sclerosis	9.82e-05	0.000266	CcSEcCtD
Ifosfamide—CYP2C18—Biological oxidations—POMC—multiple sclerosis	9.82e-05	0.00202	CbGpPWpGaD
Ifosfamide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	9.75e-05	0.00201	CbGpPWpGaD
Ifosfamide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	9.75e-05	0.00201	CbGpPWpGaD
Ifosfamide—Nausea—Triamcinolone—multiple sclerosis	9.72e-05	0.000264	CcSEcCtD
Ifosfamide—Paraesthesia—Methotrexate—multiple sclerosis	9.7e-05	0.000263	CcSEcCtD
Ifosfamide—Nausea—Methylprednisolone—multiple sclerosis	9.7e-05	0.000263	CcSEcCtD
Ifosfamide—Dyspnoea—Methotrexate—multiple sclerosis	9.64e-05	0.000261	CcSEcCtD
Ifosfamide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.62e-05	0.00198	CbGpPWpGaD
Ifosfamide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.62e-05	0.00198	CbGpPWpGaD
Ifosfamide—Somnolence—Methotrexate—multiple sclerosis	9.61e-05	0.000261	CcSEcCtD
Ifosfamide—Hypersensitivity—Prednisone—multiple sclerosis	9.53e-05	0.000258	CcSEcCtD
Ifosfamide—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.49e-05	0.00195	CbGpPWpGaD
Ifosfamide—Vomiting—Betamethasone—multiple sclerosis	9.44e-05	0.000256	CcSEcCtD
Ifosfamide—Vomiting—Dexamethasone—multiple sclerosis	9.44e-05	0.000256	CcSEcCtD
Ifosfamide—Decreased appetite—Methotrexate—multiple sclerosis	9.4e-05	0.000255	CcSEcCtD
Ifosfamide—Rash—Dexamethasone—multiple sclerosis	9.36e-05	0.000254	CcSEcCtD
Ifosfamide—Rash—Betamethasone—multiple sclerosis	9.36e-05	0.000254	CcSEcCtD
Ifosfamide—Dermatitis—Betamethasone—multiple sclerosis	9.35e-05	0.000254	CcSEcCtD
Ifosfamide—Dermatitis—Dexamethasone—multiple sclerosis	9.35e-05	0.000254	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.33e-05	0.000253	CcSEcCtD
Ifosfamide—Fatigue—Methotrexate—multiple sclerosis	9.32e-05	0.000253	CcSEcCtD
Ifosfamide—Asthenia—Prednisone—multiple sclerosis	9.28e-05	0.000252	CcSEcCtD
Ifosfamide—Pain—Methotrexate—multiple sclerosis	9.24e-05	0.000251	CcSEcCtD
Ifosfamide—Pruritus—Prednisone—multiple sclerosis	9.15e-05	0.000248	CcSEcCtD
Ifosfamide—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.09e-05	0.00187	CbGpPWpGaD
Ifosfamide—PTGS1—Selenium Micronutrient Network—IFNG—multiple sclerosis	9e-05	0.00185	CbGpPWpGaD
Ifosfamide—Feeling abnormal—Methotrexate—multiple sclerosis	8.91e-05	0.000242	CcSEcCtD
Ifosfamide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.88e-05	0.00183	CbGpPWpGaD
Ifosfamide—Diarrhoea—Prednisone—multiple sclerosis	8.85e-05	0.00024	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methotrexate—multiple sclerosis	8.84e-05	0.00024	CcSEcCtD
Ifosfamide—Nausea—Dexamethasone—multiple sclerosis	8.82e-05	0.000239	CcSEcCtD
Ifosfamide—Nausea—Betamethasone—multiple sclerosis	8.82e-05	0.000239	CcSEcCtD
Ifosfamide—Urticaria—Methotrexate—multiple sclerosis	8.59e-05	0.000233	CcSEcCtD
Ifosfamide—Dizziness—Prednisone—multiple sclerosis	8.55e-05	0.000232	CcSEcCtD
Ifosfamide—Abdominal pain—Methotrexate—multiple sclerosis	8.54e-05	0.000232	CcSEcCtD
Ifosfamide—Body temperature increased—Methotrexate—multiple sclerosis	8.54e-05	0.000232	CcSEcCtD
Ifosfamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.47e-05	0.00174	CbGpPWpGaD
Ifosfamide—Vomiting—Prednisone—multiple sclerosis	8.22e-05	0.000223	CcSEcCtD
Ifosfamide—Rash—Prednisone—multiple sclerosis	8.15e-05	0.000221	CcSEcCtD
Ifosfamide—Dermatitis—Prednisone—multiple sclerosis	8.15e-05	0.000221	CcSEcCtD
Ifosfamide—PTGS1—Selenium Micronutrient Network—IL1B—multiple sclerosis	8.03e-05	0.00165	CbGpPWpGaD
Ifosfamide—Hypersensitivity—Methotrexate—multiple sclerosis	7.96e-05	0.000216	CcSEcCtD
Ifosfamide—Asthenia—Methotrexate—multiple sclerosis	7.75e-05	0.00021	CcSEcCtD
Ifosfamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.72e-05	0.00159	CbGpPWpGaD
Ifosfamide—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.69e-05	0.00158	CbGpPWpGaD
Ifosfamide—Nausea—Prednisone—multiple sclerosis	7.68e-05	0.000208	CcSEcCtD
Ifosfamide—Pruritus—Methotrexate—multiple sclerosis	7.65e-05	0.000207	CcSEcCtD
Ifosfamide—CYP2C18—Metabolism—CYP27B1—multiple sclerosis	7.46e-05	0.00154	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—CYP24A1—multiple sclerosis	7.46e-05	0.00154	CbGpPWpGaD
Ifosfamide—Diarrhoea—Methotrexate—multiple sclerosis	7.39e-05	0.000201	CcSEcCtD
Ifosfamide—Dizziness—Methotrexate—multiple sclerosis	7.15e-05	0.000194	CcSEcCtD
Ifosfamide—CYP3A7—Metabolism—SRM—multiple sclerosis	7.04e-05	0.00145	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.98e-05	0.00144	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.98e-05	0.00144	CbGpPWpGaD
Ifosfamide—Vomiting—Methotrexate—multiple sclerosis	6.87e-05	0.000186	CcSEcCtD
Ifosfamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.87e-05	0.00141	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—SRM—multiple sclerosis	6.83e-05	0.0014	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—GPC5—multiple sclerosis	6.83e-05	0.0014	CbGpPWpGaD
Ifosfamide—Rash—Methotrexate—multiple sclerosis	6.81e-05	0.000185	CcSEcCtD
Ifosfamide—Dermatitis—Methotrexate—multiple sclerosis	6.81e-05	0.000185	CcSEcCtD
Ifosfamide—CYP3A7—Biological oxidations—POMC—multiple sclerosis	6.53e-05	0.00134	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—SRM—multiple sclerosis	6.46e-05	0.00133	CbGpPWpGaD
Ifosfamide—Nausea—Methotrexate—multiple sclerosis	6.42e-05	0.000174	CcSEcCtD
Ifosfamide—PTGS1—Biological oxidations—POMC—multiple sclerosis	6.33e-05	0.0013	CbGpPWpGaD
Ifosfamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.26e-05	0.00129	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.23e-05	0.00128	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.23e-05	0.00128	CbGpPWpGaD
Ifosfamide—CYP2A6—Biological oxidations—POMC—multiple sclerosis	5.98e-05	0.00123	CbGpPWpGaD
Ifosfamide—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	5.82e-05	0.0012	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.68e-05	0.00117	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.68e-05	0.00117	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—RRM1—multiple sclerosis	5.66e-05	0.00116	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—SRM—multiple sclerosis	5.21e-05	0.00107	CbGpPWpGaD
Ifosfamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.09e-05	0.00105	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—SRM—multiple sclerosis	5.09e-05	0.00105	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	4.96e-05	0.00102	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	4.96e-05	0.00102	CbGpPWpGaD
Ifosfamide—CYP2B6—Biological oxidations—POMC—multiple sclerosis	4.83e-05	0.000993	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—CYP24A1—multiple sclerosis	4.81e-05	0.00099	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—CYP27B1—multiple sclerosis	4.81e-05	0.00099	CbGpPWpGaD
Ifosfamide—CYP3A5—Biological oxidations—POMC—multiple sclerosis	4.72e-05	0.000971	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.7e-05	0.000967	CbGpPWpGaD
Ifosfamide—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	4.7e-05	0.000967	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	4.55e-05	0.000936	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	4.55e-05	0.000936	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—GPC5—multiple sclerosis	4.54e-05	0.000934	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—SRM—multiple sclerosis	4.41e-05	0.000907	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—GPC5—multiple sclerosis	4.4e-05	0.000905	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—GPC5—multiple sclerosis	4.16e-05	0.000856	CbGpPWpGaD
Ifosfamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.13e-05	0.00085	CbGpPWpGaD
Ifosfamide—CYP2C8—Biological oxidations—POMC—multiple sclerosis	4.09e-05	0.000841	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—SRM—multiple sclerosis	3.94e-05	0.00081	CbGpPWpGaD
Ifosfamide—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	3.93e-05	0.000809	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—RRM1—multiple sclerosis	3.76e-05	0.000774	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	3.67e-05	0.000755	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	3.67e-05	0.000755	CbGpPWpGaD
Ifosfamide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.65e-05	0.000751	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—RRM1—multiple sclerosis	3.65e-05	0.00075	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—SRM—multiple sclerosis	3.59e-05	0.000738	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	3.59e-05	0.000738	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	3.59e-05	0.000738	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—RRM1—multiple sclerosis	3.45e-05	0.000709	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—GPC5—multiple sclerosis	3.36e-05	0.000691	CbGpPWpGaD
Ifosfamide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3.33e-05	0.000684	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—GPC5—multiple sclerosis	3.28e-05	0.000675	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—BCHE—multiple sclerosis	3.25e-05	0.000669	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	3.11e-05	0.000639	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	3.11e-05	0.000639	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.04e-05	0.000625	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.84e-05	0.000585	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.83e-05	0.000582	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.78e-05	0.000572	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.77e-05	0.000571	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.77e-05	0.000571	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.72e-05	0.000559	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.71e-05	0.000558	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.54e-05	0.000522	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.53e-05	0.00052	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.53e-05	0.00052	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.47e-05	0.000509	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.43e-05	0.0005	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—SRM—multiple sclerosis	2.37e-05	0.000487	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.35e-05	0.000484	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.31e-05	0.000476	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.21e-05	0.000456	CbGpPWpGaD
Ifosfamide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.19e-05	0.000451	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—BCHE—multiple sclerosis	2.16e-05	0.000444	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.1e-05	0.000432	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—BCHE—multiple sclerosis	2.09e-05	0.000431	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—BCHE—multiple sclerosis	1.98e-05	0.000407	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—APOE—multiple sclerosis	1.95e-05	0.000402	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.92e-05	0.000394	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.83e-05	0.000376	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—POMC—multiple sclerosis	1.68e-05	0.000345	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.67e-05	0.000343	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.67e-05	0.000343	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.63e-05	0.000335	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.6e-05	0.000329	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.57e-05	0.000323	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.56e-05	0.000321	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—ALB—multiple sclerosis	1.53e-05	0.000315	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.53e-05	0.000314	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.49e-05	0.000306	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.43e-05	0.000294	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.4e-05	0.000288	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.35e-05	0.000278	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—APOE—multiple sclerosis	1.3e-05	0.000267	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.28e-05	0.000263	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.28e-05	0.000263	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.26e-05	0.00026	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—APOE—multiple sclerosis	1.26e-05	0.000259	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.21e-05	0.000248	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—APOE—multiple sclerosis	1.19e-05	0.000245	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.16e-05	0.00024	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—POMC—multiple sclerosis	1.12e-05	0.00023	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.1e-05	0.000226	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—POMC—multiple sclerosis	1.08e-05	0.000223	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—POMC—multiple sclerosis	1.02e-05	0.000211	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—ALB—multiple sclerosis	1.02e-05	0.000209	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—ALB—multiple sclerosis	9.86e-06	0.000203	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—APOE—multiple sclerosis	9.61e-06	0.000198	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—APOE—multiple sclerosis	9.39e-06	0.000193	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—ALB—multiple sclerosis	9.33e-06	0.000192	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—POMC—multiple sclerosis	8.26e-06	0.00017	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—APOE—multiple sclerosis	8.14e-06	0.000167	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—POMC—multiple sclerosis	8.07e-06	0.000166	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—ALB—multiple sclerosis	7.53e-06	0.000155	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—ALB—multiple sclerosis	7.36e-06	0.000151	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—APOE—multiple sclerosis	7.26e-06	0.000149	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.26e-06	0.000149	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—POMC—multiple sclerosis	6.99e-06	0.000144	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—APOE—multiple sclerosis	6.62e-06	0.000136	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—ALB—multiple sclerosis	6.37e-06	0.000131	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—POMC—multiple sclerosis	6.24e-06	0.000128	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—POMC—multiple sclerosis	5.69e-06	0.000117	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—ALB—multiple sclerosis	5.69e-06	0.000117	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—ALB—multiple sclerosis	5.19e-06	0.000107	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—APOE—multiple sclerosis	4.37e-06	8.98e-05	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—POMC—multiple sclerosis	3.75e-06	7.72e-05	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—ALB—multiple sclerosis	3.42e-06	7.04e-05	CbGpPWpGaD
